This article is more than 5 years old. Information may no longer be current.

Phase 2a study shows good results of ROCK inhibitor AR-12286

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

BRIDGEWATER, N.J. — A novel drug from Aerie Pharmaceuticals lowered IOP with no serious side effects in a phase 2a study, company officials announced.

David L. Epstein, MD, co-founder of Aerie Pharmaceuticals, said in a press release that he was encouraged with results of Rho-kinase (ROCK) inhibitor AR-12286.

"ROCK inhibitors such as AR-12286 act directly on the diseased tissue that is responsible for elevated intraocular pressure, the trabecular meshwork, and now it has been shown in patients to safely and effectively lower IOP," he said in the release.

The multicenter, randomized, double-masked, placebo-controlled study examined three doses of the drug in 88 patients with primary open-angle glaucoma or ocular hypertension. Patients randomly received either one of three doses or placebo.

IOP was statistically significantly lowered for once-daily and twice-daily treatments, according to the release. Change of mean IOP from baseline in the study was 28%.

The study also found no serious complications, but some patients had mild to moderate and transient hyperemia.